WO1999000110A1 - Use of tannins cross-linked in the presence of proteins non-cross-linked with the tannins - Google Patents
Use of tannins cross-linked in the presence of proteins non-cross-linked with the tannins Download PDFInfo
- Publication number
- WO1999000110A1 WO1999000110A1 PCT/FR1998/001364 FR9801364W WO9900110A1 WO 1999000110 A1 WO1999000110 A1 WO 1999000110A1 FR 9801364 W FR9801364 W FR 9801364W WO 9900110 A1 WO9900110 A1 WO 9900110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tannins
- crosslinked
- protein
- proteins
- skin
- Prior art date
Links
- 229920001864 tannin Polymers 0.000 title claims abstract description 73
- 239000001648 tannin Substances 0.000 title claims abstract description 73
- 235000018553 tannin Nutrition 0.000 title claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- 238000009499 grossing Methods 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 235000018102 proteins Nutrition 0.000 claims description 57
- 238000004132 cross linking Methods 0.000 claims description 19
- 239000003094 microcapsule Substances 0.000 claims description 17
- 108010035532 Collagen Proteins 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- 239000011859 microparticle Substances 0.000 claims description 6
- -1 soy proteins Chemical class 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010044091 Globulins Proteins 0.000 claims description 3
- 102000006395 Globulins Human genes 0.000 claims description 3
- 239000009140 Grape Seed Proanthocyanidin Substances 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 102000004407 Lactalbumin Human genes 0.000 claims description 3
- 108090000942 Lactalbumin Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 108010045569 atelocollagen Proteins 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 102000034240 fibrous proteins Human genes 0.000 claims description 3
- 108091005899 fibrous proteins Proteins 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 229940098326 grape seed proanthocyanidins Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 229940066779 peptones Drugs 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108090000371 Esterases Proteins 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000008068 Tensins Human genes 0.000 description 3
- 108010088950 Tensins Proteins 0.000 description 3
- 241000219095 Vitis Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 229940087559 grape seed Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- LXEJRKJRKIFVNY-UHFFFAOYSA-N terephthaloyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)C=C1 LXEJRKJRKIFVNY-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000920652 Quercus lusitanica Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WMPOZLHMGVKUEJ-UHFFFAOYSA-N decanedioyl dichloride Chemical compound ClC(=O)CCCCCCCCC(Cl)=O WMPOZLHMGVKUEJ-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- YVOFTMXWTWHRBH-UHFFFAOYSA-N pentanedioyl dichloride Chemical compound ClC(=O)CCCC(Cl)=O YVOFTMXWTWHRBH-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention essentially relates to the use of crosslinked tannins in the presence of proteins which are not crosslinked with the tannins as a cosmetic agent for improving the smoothing of the skin, for an astringent or firming effect.
- tannins are very old in cosmetics. When applied externally, the tannins react with the skin and mucous membranes and cause waterproofing of the most superficial layers. Tannins are also used in cosmetics for their "firming" effects linked to their astringent properties.
- the use of tannins in cosmetics is limited due to their instability in the usual cosmetic media such as gels, creams, emulsions and lotions. In particular, they produce, by degradation, colored derivatives providing an unacceptable brownish appearance.
- Tannins are also known to also have the property of precipitating proteins, in particular gelatin.
- a general method of measuring serum albumin consists of precipitating it by the tannins.
- the tannins combine with proteins, and other macromolecules, thanks to hydrogen bonds between the phenolic functions of the tannins and certain functions of the proteins.
- tannins has been made in practice impossible in cosmetics in the presence of proteins in the same product due to the tannin-protein reactivity.
- microcapsules with a wall of flavonoids crosslinked by interfacial crosslinking are described.
- the crosslinking of the flavonoids makes it possible to stabilize them and prevent any changes in color over time.
- the initial specific activity of the flavonoids is maintained (see the aims of the invention page 2, line 9 to page 3, line 24).
- crosslinked tannins combined with proteins not crosslinked with tannins, make it possible to considerably potentiate the smoothing effect of the skin, as well as to obtain a astringent effect, of a cosmetic composition containing them, and applied topically to the skin.
- the present invention aims to solve the new technical problem consisting in the supply of a solution making it possible to find a new cosmetic formulation making it possible to improve the smoothing effect of the skin, and / or obtaining an astringent effect on the skin preferably during topical application
- the present invention relates to the use of crosslinked tannins in the presence of protein not crosslinked with the tannins as a cosmetic agent for smoothing the skin, and / or for obtaining an astringent or firming effect.
- the protein is added to a solution containing the crosslinked tannins previously prepared.
- the crosslinked tannins are obtained by interfacial crosslinking, in particular in the form of a microcapsule or microparticle and the abovementioned proteins are present in a solution, in particular aqueous, containing the crosslinked tannins previously prepared.
- the concentration of. anin is between 0.001% and 5%, preferably between 0.01% and 5%, and even better between 0.1% and 1%, by weight relative to the total weight of the final composition
- the concentration of protein is between 0.01% and 10%, preferably between 0.1% and 10%, and even better between 1% and 5% by weight relative to the total weight of the final composition
- the above-mentioned tannin is a water-soluble phenolic molecule having a molecular weight of between 500 and 3,000 daltons, in particular consisting of ohgomers procyanidolic, abbreviated as OPC in the pure state, or in the form of a mixture in the form of an extract from a natural source, for example grape seed proanthocyanidins.
- tannins mention may be made of proanthocyanidols, procyanidins, picnogenols, hydrolysable tannins and in particular esters of glucose and of phenolic acids such as gallic acid and ellagic acid, and for example, officinal tannin is obtained from the gall of the oak (quercus infectoria).
- Mention may also be made of green tea extracts containing epigallocatechin, gallate and other derivatives, or extracts with complex flavonoids.
- the aforementioned protein is a protein compatible with a cosmetic or pharmaceutical application, in particular a protein of animal, human or vegetable origin such as an albumin such as serum albumin, ovalbumin, ⁇ -lactalbumin, globulins, fibrinogen, casein, collagen, atelocollagen, gelatin, gelatin hydrolysates, peptones, hemoglobin, vegetable proteins such as soy proteins, non-glytelins degraded or degraded, solubilized scleroproteins, proteins from milk in all its forms, soy flour.
- an albumin such as serum albumin, ovalbumin, ⁇ -lactalbumin, globulins, fibrinogen, casein, collagen, atelocollagen, gelatin, gelatin hydrolysates, peptones, hemoglobin, vegetable proteins such as soy proteins, non-glytelins degraded or degraded, solubilized scleroproteins, proteins from milk in all its forms, soy flour.
- the present invention also covers a process for the manufacture of a composition which is stable over time and contains tannins, in particular procyanidolic or OPC oligomers, in the presence of a protein, characterized in that one carries out in a first step the crosslinking of the tannins, in the absence of said protein, and in a second step, the crosslinked tannins are mixed with said protein.
- a reaction medium containing the crosslinked tannins as such into which said protein is added, or else to separate the crosslinked tannins and to introduce them into a solution containing the protein, in particular to an aqueous solution.
- the crosslinking of the tannins takes place by interfacial crosslinking, and in the currently preferred case where the tannins are water-soluble, the interfacial crosslinking is carried out on an emulsion in which the dispersed phase is an aqueous phase containing the tannins in solubilized form, by an interfacial crosslinking agent present in a continuous hydrophobic phase.
- This interfacial crosslinking technique is advantageously that described in document FR-A-2 715 582 which is incorporated here by reference, in particular from page 6, line 30 to page 10, line 22, as well as manufacturing examples 1 to 25.
- the crosslinking agent comprises a diacid chloride, preferably chosen from the group consisting of an aliphatic or aromatic diacid chloride, such as sebacoyl chloride, succinyl chloride, apipoyl chloride, terephthaloyl chloride, glutaryl chloride.
- concentration of diacid chloride will preferably be between 0.2% and 10% by weight of the total weight of the reaction medium.
- liquid substances used to constitute the hydrophobic phase it is possible to use liquid substances well known to those skilled in the art such as those mentioned on page 8, lines 7 to 14, and in particular fatty acid esters such as isopropyl myristate or ethyl oleate, mixtures of fatty acid esters commercially available such as for example the product Dragoxat ®, sold by the company Dragoco, vegetable oils, such as liquid olive, sweet almond oil, peanut oil, mineral oils, such as paraffin oil and any mixture of these liquid and hydrophobic substances. It is understandable that vegetable oils are particularly interesting since they are compatible with a cosmetic or pharmaceutical application.
- the crosslinked tannins can advantageously be in the form of microcapsules or microparticles during crosslinking by interfacial crosslinking. These microcapsules or microparticles generally have a diameter lying in the range between 0.1 ⁇ m and 3 mm.
- the first step of the process of the invention consists in carrying out beforehand the crosslinking of the tannins, in the absence of proteins, and can be carried out in accordance with Example 1 of FR-A-2 715 582.
- Example 5 During the crosslinking of tannins constituted by procyanidolic oligomers of grape seeds, abbreviated OPC PR, the conditions of Example 5 can be used, which are combined with the protocol described in Example 1 of FR-A-2 715 582.
- the present invention also covers a method of cosmetic treatment of the skin, to improve the smoothing of the skin, to obtain an astringent effect on the skin, in particular a firming effect, characterized in that it comprises the application to the affected areas of the skin of an effective amount of crosslinked tannins in combination with proteins not crosslinked with the tannins
- composition comprising crosslinked tannins in the form of crosslinked grape seed proanthocvanidines, combined with a protein obtained from wheat, commercially available under the name of Tensine® from the company Silab® France
- an aqueous phase is first prepared by dissolving 300 mg of a solution of procyanidolic oligomers of grape seeds, commercial references OPC PR, marketed by the company Sarpap, France, in 3 ml of a buffer. carbonate PH 11, or approximately 10% OPC.
- the microcapsules prepared in step a) are separated from the aqueous suspension containing them by cent ⁇ fugation.
- washings are carried out to eliminate the reaction medium.
- the microcapsules thus washed can be mixed with an aqueous solution containing wheat protein.
- compositions comprising various concentrations of crosslinked tannins, and proteins, as is well understood by those skilled in the art.
- a test without OPC determines the quantity of albumin serum actually present in the supernatant and also defines the 100% of non-precipitated albumin serum.
- the assay technique used is the Coomasie blue method with a reading of the optical density respectively at a wavelength of 590 nanometers and a wavelength of 465 nanometers to measure the absorbance called respectively Abs 59 o at 590 nanometers and Abs 465 at 465 nanometers.
- the Abs 5 o / Abs 65 ratio makes it possible to determine the protein concentration as is easily understood by those skilled in the art.
- the precipitation curve for bovine serum albumin or BSA shown in FIG. 1 is thus obtained, which represents the tannin concentration of 0 to 1 ng / ml on the abscissa and the% in soluble bovine serum albumin (BSA) on the ordinate.
- Curve 1 is the control curve without tannin
- curve 2 is the curve obtained with crosslinked tannins, here crosslinked OPCs
- curve 3 is the curve obtained with free tannins, here free or uncrosslinked OPCs.
- FIG. 2 represents on the abscissa the concentration in% of OPC which varies from 0 to 0.25%, as a function of the relative viscosity on the ordinate for a constant concentration of type 1 collagen of 0 0.05% in water at 29 ° C.
- Curve 1 is obtained with the control collagen solution
- curve 2 is obtained by adding an increasing concentration of free OPC
- curve 3 is obtained by adding to the collagen solution an increasing concentration of crosslinked OPCs, obtained according to example).
- OPC microcapsules are used as obtained in example la. These OPC microcapsules are formed following the establishment of ester bonds. The membrane that forms is therefore made up of esterified flavonoids. It is demonstrated by the present test that under the action of esterase, there is release over time of procyanidol monomers. The present test consists in bringing together 286 esterase units, constituted by an E 3019 esterase from the porcine pancreas commercially available from Sigma, with crosslinked OPCs according to example la, and after centrifugation at different times. (30 min; 1 hour; 2 hours; 3 hours; 4 hours and 6 hours), the composition of the supernatant is visualized by HPLC chromatography.
- esterases are secreted from Ocland bodies in the stratum granulosum which will migrate to the surface of the stratum corneum.
- the presence of esterases in the surface layer of the skin will allow an attack on the crosslinked OPC microcapsules and thus release the procyanidic oligomers endowed with tanning properties and which will crosslink the collagen present in the surface layer of the skin. and thus provide the smoothing effect of the skin demonstrated by the present invention, which is confirmed by the smoothing tests below.
- Example 1 Each person received on different skin areas of one of the forearms, 4 different compositions according to the invention, as prepared in Example 1. On a skin area of the other forearm, they receive a control composition consisting solely of the excipient of said compositions of Example 1.
- the + indication signifies an insignificant skin smoothing effect
- the indication ++ means a slight smoothing of the skin
- the indication +++ means a marked reduction in wrinkles and a fairly satisfactory smoothing of the skin
- the indication ++++ signifies a very marked reduction in the depth of wrinkles and a very satisfactory smoothing of the skin.
- the concentrations of protein (tensin) and of tannins, namely of proanthocyanidolic oligomers of crosslinked grape seeds (crosslinked OPC PR ) are expressed as a percentage by weight, relative to the total weight of the final composition. .
- composition called "radiance boost” to smooth facial skin
- composition is prepared from the following ingredients: - crosslinked OPC microcapsules, according to example 1 g,
- this composition the 5 g of tensin are dissolved in approximately 40 g of distilled water, cold with mechanical stirring, then 1 g of the crosslinked OPC microcapsules prepared according to Example 1a is dispersed. While maintaining stirring, make up to 50 g with an aqueous excipient containing the perfume and the preservatives. Then added 50 g of a 0.1% Carbopol 940 gel neutralized with sodium hydroxide prepared separately.
- a composition is thus obtained in the form of a gel which, applied to the skin of the face, produces in a few minutes a tightening effect which smoothes the skin by reducing wrinkles and fine lines.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention concerns the use of tannins cross-linked in the presence of proteins non-cross-linked with the tannins as cosmetic agents to improve skin smoothing and/or to obtain an astringent effect. The invention also concerns a method for making a composition stable in time containing tannins in the presence of a protein, characterised in that in a first step, the tannins are cross-linked in the absence of said protein and in a second step the cross-linked tannins are mixed with said protein. The invention provides a method for the cosmetic treatment of the skin or for improving skin smoothing and/or for producing an astringent effect on the skin, in particular a toning effect.
Description
UTILISAΗON DE TANINS RETICULES EN PRESENCE DE PROTEINES NON RETICULEES AVEC LES TANINSUSE OF CROSSLINKED TANNINS IN THE PRESENCE OF PROTEINS NOT CROSSLINKED WITH TANNINS
L'invention concerne essentiellement l'utilisation de tanins réticulés en présence de protéines non réticulées avec les tanins comme agent cosmétique pour améliorer le lissage de la peau, pour un effet astringent, ou raffermissant.The invention essentially relates to the use of crosslinked tannins in the presence of proteins which are not crosslinked with the tannins as a cosmetic agent for improving the smoothing of the skin, for an astringent or firming effect.
L'utilisation de tanins est très ancienne en cosmétique. En application externe, les tanins réagissent avec la peau et les muqueuses et provoquent une imperméabilisation des couches les plus superficielles. Les tanins sont également utilisés en cosmétique pour leurs effets "raffermissant" liés à leurs propriétés astringentes. L'utilisation des tanins en cosmétique est limitée en raison de leur instabilité dans les milieux cosmétiques habituels tels que gels, crèmes, émulsions et lotions. En particulier, ils produisent par dégradation des dérivés colorés apportant un aspect brunâtre inacceptable.The use of tannins is very old in cosmetics. When applied externally, the tannins react with the skin and mucous membranes and cause waterproofing of the most superficial layers. Tannins are also used in cosmetics for their "firming" effects linked to their astringent properties. The use of tannins in cosmetics is limited due to their instability in the usual cosmetic media such as gels, creams, emulsions and lotions. In particular, they produce, by degradation, colored derivatives providing an unacceptable brownish appearance.
Les tanins sont également connus comme ayant aussi la propriété de précipiter les protéines, en particulier la gélatine.Tannins are also known to also have the property of precipitating proteins, in particular gelatin.
Ainsi, une méthode générale de dosage de la sérum albumine consiste à la précipiter par les tanins. Les tanins se combinent avec les protéines, et d'autres macromolécules, grâce à des liaisons hydrogènes entre les fonctions phénoliques des tanins et certaines fonctions des protéines.Thus, a general method of measuring serum albumin consists of precipitating it by the tannins. The tannins combine with proteins, and other macromolecules, thanks to hydrogen bonds between the phenolic functions of the tannins and certain functions of the proteins.
Dans ces circonstances, l'utilisation des tanins a été rendue en pratique impossible en cosmétique en présence de protéines dans le même produit du fait de la réactivité tanin-protéine.Under these circumstances, the use of tannins has been made in practice impossible in cosmetics in the presence of proteins in the same product due to the tannin-protein reactivity.
Dans la demande de brevet FR-A-2 715 582 du- CNRS, il est décrit des microcapsules à paroi de flavonoïdes réticulés par réticulation interfaciale. La réticulation des flavonoïdes permet de les stabiliser et de prévenir toutes les modifications de coloration au cours du temps. En outre, l'activité initiale spécifique des flavonoïdes est maintenue (voir les buts de l'invention page 2, ligne 9 à page 3, ligne 24).In patent application FR-A-2 715 582 of the CNRS, microcapsules with a wall of flavonoids crosslinked by interfacial crosslinking are described. The crosslinking of the flavonoids makes it possible to stabilize them and prevent any changes in color over time. In addition, the initial specific activity of the flavonoids is maintained (see the aims of the invention page 2, line 9 to page 3, line 24).
L'addition de protéines, présente initialement, est prévue dans un mode de réalisation particulier de sorte que la protéine est coréticulée avec le flavonoïde
(page 4, ligne 11 à 15, et les exemples 3, 4, 6, 8, 10, 11, 13, 14, 16, 25 ainsi que les revendications 2 et 3 notamment).The addition of proteins, initially present, is provided in a particular embodiment so that the protein is co-crosslinked with the flavonoid (page 4, line 11 to 15, and examples 3, 4, 6, 8, 10, 11, 13, 14, 16, 25 as well as claims 2 and 3 in particular).
Dans le cadre de la présente invention, il vient d'être découvert de manière inattendue que les tanins réticulés, combinés à des protéines non réticulées avec les tanins, permettaient de potentialiser considérablement l'effet de lissage de la peau, ainsi que pour obtenir un effet astringent, d'une composition cosmétique les contenant, et appliques topiquement sur la peau.In the context of the present invention, it has just been unexpectedly discovered that crosslinked tannins, combined with proteins not crosslinked with tannins, make it possible to considerably potentiate the smoothing effect of the skin, as well as to obtain a astringent effect, of a cosmetic composition containing them, and applied topically to the skin.
Ainsi, selon un premier aspect, la présente invention a pour but de résoudre le nouveau problème technique consistant en la fourniture d'une solution permettant de trouver une nouvelle formulation cosmétique permettant d'améliorer l'effet de lissage de la peau, et/ou l'obtention d'un effet astringent sur la peau de préférence lors d'une application topiqueThus, according to a first aspect, the present invention aims to solve the new technical problem consisting in the supply of a solution making it possible to find a new cosmetic formulation making it possible to improve the smoothing effect of the skin, and / or obtaining an astringent effect on the skin preferably during topical application
Ce nouveau problème technique est résolu par la présente invention d'une manière, sûre et fiable, utilisable à l'échelle industrielle. Ainsi, selon un premier aspect, la présente invention concerne l'utilisation de tanins réticulés en présence de protéine non réticulées avec les tanins comme agent cosmétique pour le lissage de la peau, et/ou pour l'obtention d'un effet astringent ou raffermissantThis new technical problem is solved by the present invention in a manner, safe and reliable, usable on an industrial scale. Thus, according to a first aspect, the present invention relates to the use of crosslinked tannins in the presence of protein not crosslinked with the tannins as a cosmetic agent for smoothing the skin, and / or for obtaining an astringent or firming effect.
Selon une vaπante de réalisation particulière, la protéine est ajoutée à une solution contenant les tanins réticulés préalablement préparés.According to a particular embodiment, the protein is added to a solution containing the crosslinked tannins previously prepared.
Selon un mode de réalisation actuellement préféré, les tanins réticulés sont obtenus par réticulation interfaciale, en particulier sous forme de microcapsule ou microparticule et les protéines précitées sont présentes dans une solution, en particulier aqueuse, contenant les tanins réticulés préalablement préparés.According to a currently preferred embodiment, the crosslinked tannins are obtained by interfacial crosslinking, in particular in the form of a microcapsule or microparticle and the abovementioned proteins are present in a solution, in particular aqueous, containing the crosslinked tannins previously prepared.
Dans le cadre de l'invention, la concentration en. anin est comprise entre 0,001 % et 5 %, de préférence entre 0,01 % et 5 %, et encore mieux entre 0,1 % et 1 %, en poids par rapport au poids total de la composition finale, tandis que la concentration en protéine est comprise entre 0,01 % et 10 %, de préférence entre 0,1 % et 10 %, et encore mieux entre 1 % et 5 % en poids par rapport au poids total de la composition finaleIn the context of the invention, the concentration of. anin is between 0.001% and 5%, preferably between 0.01% and 5%, and even better between 0.1% and 1%, by weight relative to the total weight of the final composition, while the concentration of protein is between 0.01% and 10%, preferably between 0.1% and 10%, and even better between 1% and 5% by weight relative to the total weight of the final composition
Selon un mode de réalisation avantageux de l'invention, le tanin précité est une molécule phénohque hydrosoluble ayant un poids moléculaire compris entre 500 et 3 000 daltons, en particulier constitué par des ohgomères
procyanidoliques, en abrégé dénommé OPC à l'état pur, ou à l'état de mélange sous forme d'extrait de source naturelle, par exemple des proanthocyanidines de pépins de raisin. Comme autres tanins, on peut citer les proanthocyanidols, les procyanidines, les picnogénols, les tanins hydrolysables et notamment des esters de glucose et d'acides phénoliques tels que l'acide gallique et l'acide ellagique, et par exemple, le tanin officinal est obtenu à partir de la galle du chêne (quercus infectoria).According to an advantageous embodiment of the invention, the above-mentioned tannin is a water-soluble phenolic molecule having a molecular weight of between 500 and 3,000 daltons, in particular consisting of ohgomers procyanidolic, abbreviated as OPC in the pure state, or in the form of a mixture in the form of an extract from a natural source, for example grape seed proanthocyanidins. As other tannins, mention may be made of proanthocyanidols, procyanidins, picnogenols, hydrolysable tannins and in particular esters of glucose and of phenolic acids such as gallic acid and ellagic acid, and for example, officinal tannin is obtained from the gall of the oak (quercus infectoria).
On peut également citer les extraits de thé vert contenant de l'épigallocatéchine, gallate et d'autres dérivés, ou des extraits à flavonoïdes complexes.Mention may also be made of green tea extracts containing epigallocatechin, gallate and other derivatives, or extracts with complex flavonoids.
Dans le cadre de l'invention, la protéine précitée est une protéine compatible avec une application cosmétique ou pharmaceutique, en particulier une protéine d'origine animale, humaine ou végétale telle qu'une albumine comme la sérum albumine, l'ovalbumine, l'α-lactalbumine, les globulines, le fibrinogène, la caséine, le collagène, l'atélocollagène, la gélatine, les hydrolysats de gélatine, les peptones, l'hémoglobine, les protéines végétales telles que les protéines du soja, des glytélines sous forme non dégradée ou dégradée, des scléroprotéines solubilisées, des protéines issues du lait sous toutes ses formes, la farine de soja.In the context of the invention, the aforementioned protein is a protein compatible with a cosmetic or pharmaceutical application, in particular a protein of animal, human or vegetable origin such as an albumin such as serum albumin, ovalbumin, α-lactalbumin, globulins, fibrinogen, casein, collagen, atelocollagen, gelatin, gelatin hydrolysates, peptones, hemoglobin, vegetable proteins such as soy proteins, non-glytelins degraded or degraded, solubilized scleroproteins, proteins from milk in all its forms, soy flour.
Selon un troisième aspect, la présente invention couvre également un procédé de fabrication d'une composition stable dans le temps contenant des tanins en particulier des oligomères procyanidoliques ou OPC, en présence d'une protéine, caractérisé en ce que l'on réalise dans une première étape la réticulation des tanins, en l'absence de ladite protéine, et dans une deuxième étape, on mélange les tanins réticulés avec ladite protéine. Pour réaliser ce mélange, on peut soit utiliser le milieu reactionnel contenant les tanins réticulés tels quels dans lequel on ajoute ladite protéine, soit encore séparer les tanins réticulés et les introduire dans une solution contenant la protéine, en particulier à une solution aqueuse.According to a third aspect, the present invention also covers a process for the manufacture of a composition which is stable over time and contains tannins, in particular procyanidolic or OPC oligomers, in the presence of a protein, characterized in that one carries out in a first step the crosslinking of the tannins, in the absence of said protein, and in a second step, the crosslinked tannins are mixed with said protein. To achieve this mixture, it is possible either to use the reaction medium containing the crosslinked tannins as such into which said protein is added, or else to separate the crosslinked tannins and to introduce them into a solution containing the protein, in particular to an aqueous solution.
Selon un mode de réalisation avantageux de l'invention, la réticulation des tanins a lieu par réticulation interfaciale, et dans le cas actuellement préféré où les tanins sont hydrosolubles, la réticulation interfaciale est réalisée sur une émulsion dans laquelle la phase dispersée est une phase aqueuse contenant les tanins sous forme solubilisée, par un agent de réticulation interfaciale présent dans une phase hydrophobe continue. Cette technique de réticulation interfaciale est avantageusement celle décrite dans le document FR-A-2 715 582 qui est incorporé
ici par référence, en particulier de la page 6, ligne 30 à la page 10, ligne 22, ainsi que les exemples de fabrication 1 à 25. On observera en particulier que l'agent réticulant comprend un chlorure de diacide, de préférence choisi parmi le groupe consistant d'un chlorure de diacide aliphatique ou aromatique, tel que le chlorure de sébacoyle, le chlorure de succinyle, le chlorure d'apipoyle, le chlorure de téréphtaloyle, le chlorure de glutaryle. La concentration en chlorure de diacide sera de préférence comprise entre 0,2 % et 10 % en poids du poids total du milieu reactionnel. Comme substances utilisées pour constituer la phase hydrophobe, on pourra utiliser des substances liquides bien connues de l'homme de l'art telles que celles citées à la page 8, lignes 7 à 14, et en particulier des esters d'acide gras tels que le myristate d'isopropyle ou l'oléate d'éthyle, des mélanges d'esters d'acide gras disponibles dans le commerce tels que par exemple le produit Dragoxat®, commercialisé par la firme Dragoco, des huiles végétales, telles que l'huile d'olive, l'huile d'amande douce, l'huile d'arachide, les huiles minérales, telles qu'une huile de paraffine et tout mélange de ces substances liquides et hydrophobes. Il est bien compréhensible que les huiles végétales sont particulièrement intéressantes puisqu'elles sont compatibles avec une application cosmétique ou pharmaceutique. 11 est également possible d'utiliser des agents tensioactifs pour faciliter la préparation de l'émulsion comme décrit en page 8, lignes 15 à 22 de FR-A-2 715 582 où l'homme de l'art pourra se reporter. Ainsi, les tanins réticulés peuvent se présenter avantageusement sous forme de microcapsules ou de microparticules lors d'une réticulation par réticulation interfaciale. Ces microcapsules ou microparticules présentent généralement un diamètre se situant dans l'intervalle compris entre 0, 1 μm et 3 mm. La première étape du procédé de l'invention consiste à réaliser préalablement la réticulation des tanins, en l'absence de protéines, et peut être réalisée conformément à l'exemple 1 de FR-A-2 715 582.According to an advantageous embodiment of the invention, the crosslinking of the tannins takes place by interfacial crosslinking, and in the currently preferred case where the tannins are water-soluble, the interfacial crosslinking is carried out on an emulsion in which the dispersed phase is an aqueous phase containing the tannins in solubilized form, by an interfacial crosslinking agent present in a continuous hydrophobic phase. This interfacial crosslinking technique is advantageously that described in document FR-A-2 715 582 which is incorporated here by reference, in particular from page 6, line 30 to page 10, line 22, as well as manufacturing examples 1 to 25. It will be observed in particular that the crosslinking agent comprises a diacid chloride, preferably chosen from the group consisting of an aliphatic or aromatic diacid chloride, such as sebacoyl chloride, succinyl chloride, apipoyl chloride, terephthaloyl chloride, glutaryl chloride. The concentration of diacid chloride will preferably be between 0.2% and 10% by weight of the total weight of the reaction medium. As substances used to constitute the hydrophobic phase, it is possible to use liquid substances well known to those skilled in the art such as those mentioned on page 8, lines 7 to 14, and in particular fatty acid esters such as isopropyl myristate or ethyl oleate, mixtures of fatty acid esters commercially available such as for example the product Dragoxat ®, sold by the company Dragoco, vegetable oils, such as liquid olive, sweet almond oil, peanut oil, mineral oils, such as paraffin oil and any mixture of these liquid and hydrophobic substances. It is understandable that vegetable oils are particularly interesting since they are compatible with a cosmetic or pharmaceutical application. It is also possible to use surfactants to facilitate the preparation of the emulsion as described on page 8, lines 15 to 22 of FR-A-2 715 582 where a person skilled in the art may refer. Thus, the crosslinked tannins can advantageously be in the form of microcapsules or microparticles during crosslinking by interfacial crosslinking. These microcapsules or microparticles generally have a diameter lying in the range between 0.1 μm and 3 mm. The first step of the process of the invention consists in carrying out beforehand the crosslinking of the tannins, in the absence of proteins, and can be carried out in accordance with Example 1 of FR-A-2 715 582.
Lors de la réticulation de tanins constitués par des oligomères procyanidoliques de pépins de raisin, en abrégé OPC PR, on pourra utiliser les conditions de l'exemple 5, qui sont combinés au protocole décrit à l'exemple 1 de FR-A-2 715 582.During the crosslinking of tannins constituted by procyanidolic oligomers of grape seeds, abbreviated OPC PR, the conditions of Example 5 can be used, which are combined with the protocol described in Example 1 of FR-A-2 715 582.
Selon un quatrième aspect, la présente invention couvre encore un procédé de traitement cosmétique de la peau, pour améliorer le lissage de la peau, pour obtenir un effet astringent sur la peau, en particulier un effet raffermissant,
caractérisé en ce qu'il comprend l'application sur les zones de la peau concernées d'une quantité efficace de tanins réticulés en combinaison avec des protéines non réticulées avec les taninsAccording to a fourth aspect, the present invention also covers a method of cosmetic treatment of the skin, to improve the smoothing of the skin, to obtain an astringent effect on the skin, in particular a firming effect, characterized in that it comprises the application to the affected areas of the skin of an effective amount of crosslinked tannins in combination with proteins not crosslinked with the tannins
D'autres vanantes de réalisation de ce procédé de traitement cosmétique résultent de la description précédente relativement à l'un ou l'autre des trois premiers aspects, ainsi que des revendications.Other aspects of carrying out this cosmetic treatment process result from the preceding description relating to one or other of the first three aspects, as well as from the claims.
La présente invention va maintenant être décrite en relation avec un exemple actuellement préféré de l'invention donné simplement à titre d'illustration et qui ne saurait donc en aucune façon limiter la portée de l'invention, avec démonstration de l'activité de lissage de la peau, des exemples de formulations cosmétiques ou pharmaceutiques étant ensuite donnés également à titre d'illustration.The present invention will now be described in relation to a currently preferred example of the invention given simply by way of illustration and which therefore cannot in any way limit the scope of the invention, with demonstration of the smoothing activity of the skin, examples of cosmetic or pharmaceutical formulations being then also given by way of illustration.
Exemple 1 de l'inventionExample 1 of the invention
Préparation d'une composition comprenant des tanins réticulés sous forme de proanthocvanidines de pépins de raisin réticulés, combinés avec une protéine issue du blé, disponible dans le commerce sous le nom de Tensine® de la société Silab® FrancePreparation of a composition comprising crosslinked tannins in the form of crosslinked grape seed proanthocvanidines, combined with a protein obtained from wheat, commercially available under the name of Tensine® from the company Silab® France
Les étapes de procédé de préparation de cette composition sont les suivantesThe process steps for preparing this composition are as follows
a) Etape de réticulation des proanthocvanidines (OPC) de pépins de raisin Pour réaliser cette étape, on procède comme décrit à l'exemple 5 de FR-a) Cross-linking step of grape seed proanthocvanidins (OPC) To carry out this step, the procedure is carried out as described in Example 5 of FR-
A-2 715 582.A-2,715,582.
Pour ce faire, on prépare tout d'abord une phase aqueuse en dissolvant 300 mg d'une solution d'oligomères procyanidoliques de pépins de raism, références commerciales OPC PR, commercialisé par la société Sarpap, France, dans 3 ml d'un tampon carbonate PH 11, soit environ une proportion de 10 % en OPC. On procède ensuite à une émulsification en émulsionnant 3 ml de cette solution dans 15 ml de cyclohexane additionné de 5 % d'un agent tensioactif, tel que le Span 85® (tπoléate de sorbitan), par agitation à 3 000 rpm
Ensuite, après 5 mm d'agitation, on ajoute à l'émulsion 20 ml d'une solution à 5 % en poids/volume d'agents réticulants constitués par le chlorure de téréphtaloyle (CF) commercialisé par Janssen Chimica, dans un mélange de chloroforme . cyclohexane dans un rapport 1.4 volume/volume et on maintient l'agitation pendant 30 minutesTo do this, an aqueous phase is first prepared by dissolving 300 mg of a solution of procyanidolic oligomers of grape seeds, commercial references OPC PR, marketed by the company Sarpap, France, in 3 ml of a buffer. carbonate PH 11, or approximately 10% OPC. To emulsification is then carried out by emulsifying three ml of this solution in 15 ml of cyclohexane with 5% of a surfactant such as Span ® 85 (sorbitan tπoléate) by stirring at 3000 rpm Then, after 5 mm of stirring, 20 ml of a 5% w / v solution of crosslinking agents consisting of terephthaloyl chloride (CF) sold by Janssen Chimica are added to the emulsion. chloroform. cyclohexane in a 1.4 volume / volume ratio and stirring is continued for 30 minutes
On procède ensuite a une séparation des microcapsules obtenues par centπfugation et lavage par remise en suspension successivement dans le cyclohexane, dans l'alcool à 95 % additionné de 2 % de Tween 20 dans l'alcool à 95 % et finalement dans l'eau distillée L'examen microscope optique montre de belles microcapsules sphéπques, transparentes de diamètres 5-25 μm, à l'état de suspension aqueuse.One then proceeds to a separation of the microcapsules obtained by centπfugation and washing by resuspension successively in cyclohexane, in 95% alcohol added with 2% Tween 20 in 95% alcohol and finally in distilled water The optical microscope examination shows beautiful spherical, transparent microcapsules with diameters 5-25 μm, in the form of an aqueous suspension.
b) Préparation du mélange tanins réticulés-protéines de bléb) Preparation of the crosslinked tannin-wheat protein mixture
Selon une première vaπante de réalisation, on sépare les microcapsules préparées à l'étape a) de la suspension aqueuse les contenant par centπfugation.According to a first variant, the microcapsules prepared in step a) are separated from the aqueous suspension containing them by centπfugation.
On réalise des lavages pour éliminer le milieu reactionnel. Les microcapsules ainsi lavées peuvent être mélangées à une solution aqueuse contenant la protéine de blé.Washings are carried out to eliminate the reaction medium. The microcapsules thus washed can be mixed with an aqueous solution containing wheat protein.
En faisant varier les proportions respectives de microcapsules et de protéines de blé, on obtient diverses compositions comprenant diverses concentrations en tanins réticulés, et en protéines, comme cela est bien compréhensible à l'homme de l'art.By varying the respective proportions of microcapsules and wheat proteins, various compositions are obtained comprising various concentrations of crosslinked tannins, and proteins, as is well understood by those skilled in the art.
Ainsi, diverses compositions ont été préparées et elles sont rapportées au tableau III de résultat de l'exemple 5 donné ci-aprèsThus, various compositions were prepared and they are reported in Table III of the result of Example 5 given below.
Exemple 2 de l'inventionExample 2 of the invention
Test de précipitation de la sérum albumine bovine par des concentrations croissantes de proanthocvanidines (OPC) libres et réticulésBovine serum albumin precipitation test with increasing concentrations of free and crosslinked proanthocvanidins (OPC)
Pour réaliser ce test, on utilise une dose constante de sérum albumine bovine du commerce, mise en contact avec des doses croissantes d'OPC libres ou réticuléesTo carry out this test, a constant dose of commercial bovine serum albumin is used, brought into contact with increasing doses of free or crosslinked OPCs.
Apres 15 minutes d'incubation à température ambiante, on effectue une centπfugation afin d'éliminer la sérum albumine éventuellement précipitée
Un dosage de protéines est fait sur le surnageant.After 15 minutes of incubation at room temperature, a centrifugation is carried out in order to eliminate the albumin serum which may be precipitated. A protein assay is made on the supernatant.
Un essai sans OPC détermine la quantité de sérum albumine effectivement présente dans le surnageant et définit aussi le 100 % de sérum albumine non précipitée.A test without OPC determines the quantity of albumin serum actually present in the supernatant and also defines the 100% of non-precipitated albumin serum.
La technique de dosage mise en oeuvre est la méthode au bleu de Coomasie avec une lecture de la densité optique respectivement à une longueur d'onde de 590 nanomètres et une longueur d'onde de 465 nanomètres pour mesurer l'absorbance dénommée respectivement Abs59o à 590 nanomètres et Abs465 à 465 nanomètres. Le rapport Abs5 o/Abs 65 permet de déterminer la concentration protéique comme cela est bien compréhensible à l'homme de l'art.The assay technique used is the Coomasie blue method with a reading of the optical density respectively at a wavelength of 590 nanometers and a wavelength of 465 nanometers to measure the absorbance called respectively Abs 59 o at 590 nanometers and Abs 465 at 465 nanometers. The Abs 5 o / Abs 65 ratio makes it possible to determine the protein concentration as is easily understood by those skilled in the art.
Les valeurs du tableau I ci-dessous sont exprimées en pourcentage de sérum albumine bovine ou BSA non-précipitée.The values in Table I below are expressed as a percentage of non-precipitated bovine serum albumin or BSA.
Tableau I ; mesure de BSA non-précipitée en pourcentage en poidsTable I; non-precipitated BSA measurement as a percentage by weight
On obtient ainsi la courbe de précipitation de la sérum albumine bovine ou BSA représentée à la figure 1 qui représente en abscisse la concentration en tanin de 0 à 1 ng/ml et en ordonnée le % en sérum albumine bovine (BSA) soluble.The precipitation curve for bovine serum albumin or BSA shown in FIG. 1 is thus obtained, which represents the tannin concentration of 0 to 1 ng / ml on the abscissa and the% in soluble bovine serum albumin (BSA) on the ordinate.
La courbe 1 est la courbe témoin sans tanin, la courbe 2 est la courbe obtenue avec des tanins réticulés, ici des OPC réticulés et la courbe 3 est la courbe obtenue avec des tanins libres, ici des OPC libres ou non réticulés.Curve 1 is the control curve without tannin, curve 2 is the curve obtained with crosslinked tannins, here crosslinked OPCs and curve 3 is the curve obtained with free tannins, here free or uncrosslinked OPCs.
On constate à partir du tableau I et de la figure 1 que lorsque les OPC sont réticulés, il n'y a essentiellement pas de précipitation de la protéine, contrairement aux OPC Libres.
Exemple 3 de l'inventionIt can be seen from Table I and FIG. 1 that when the OPCs are crosslinked, there is essentially no precipitation of the protein, unlike the Free OPCs. Example 3 of the invention
Test d'interaction entre le collagène de type 1 et les OPC libres ou réticulés L'interaction collagène-tanin due à l'expression de liaisons hydrogènes se traduit par une augmentation du taux de réticulation du collagène et par conséquent de sa viscosité.Interaction test between type 1 collagen and free or crosslinked OPCs The collagen-tannin interaction due to the expression of hydrogen bonds results in an increase in the crosslinking rate of collagen and consequently in its viscosity.
Dans ce test, une concentration constante de collagène de type 1 est mise en présence de concentration croissante d'OPC libre et réticulé. On mesure la viscosité du mélange grâce à un viscosimètre deIn this test, a constant concentration of type 1 collagen is brought into contact with an increasing concentration of free and crosslinked OPC. The viscosity of the mixture is measured using a viscometer of
Ubbelohde, disponible dans le commerce, bien connu à l'homme de l'art, réf. 0,78 IT, à une température de 29°C.Ubbelohde, commercially available, well known to those skilled in the art, ref. 0.78 IT, at a temperature of 29 ° C.
Les résultats de cet essai sont rapportés à la figure 2 qui représente en abscisse la concentration en % en OPC qui varie de 0 à 0,25 %, en fonction de la viscosité relative en ordonnée pour une concentration constante de collagène de type 1 de 0,05 % dans de l'eau à 29°C.The results of this test are reported in FIG. 2 which represents on the abscissa the concentration in% of OPC which varies from 0 to 0.25%, as a function of the relative viscosity on the ordinate for a constant concentration of type 1 collagen of 0 0.05% in water at 29 ° C.
La courbe 1 est obtenue avec la solution de collagène témoin, la courbe 2 est obtenue en ajoutant une concentration croissante en OPC libre et la courbe 3 est obtenue en ajoutant à la solution de collagène une concentration croissante d'OPC réticulés, obtenus selon l'exemple la).Curve 1 is obtained with the control collagen solution, curve 2 is obtained by adding an increasing concentration of free OPC and curve 3 is obtained by adding to the collagen solution an increasing concentration of crosslinked OPCs, obtained according to example).
Ce deuxième test confirme l'absence de phénomène de pontage entre les protéines et les OPC réticulés contrairement au phénomène observé bien connu avec les OPC libres.This second test confirms the absence of a bridging phenomenon between proteins and crosslinked OPCs, unlike the well-known phenomenon observed with free OPCs.
Exemple 4 de l'inventionExample 4 of the invention
Test de cinétique d'hydrolyse par une estérase des OPC réticulésHydrolysis kinetics test with crosslinked OPC esterase
On utilise les microcapsules d'OPC telles qu'obtenues à l'exemple la. Ces microcapsules d'OPC sont formées à la suite de l'établissement de liaisons esters. La membrane qui se forme est donc constituée de flavonoïdes estérifiés. Il est démontré par le présent test que sous l'action d'estérase, il y a libération au cours du temps de monomères procyanidoliques.
Le présent test consiste à mettre en présence 286 unités d'estérase, constituées par une estérase E 3019 d'origine du pancréas de porc disponible dans le commerce chez Sigma, avec des OPC réticulés selon l'exemple la, et après centrifugation à différents temps (30 mn ; 1 heure ; 2 heures ; 3 heures ; 4 heures et 6 heures), la composition du surnageant est visualisée par chromatographie HPLC.OPC microcapsules are used as obtained in example la. These OPC microcapsules are formed following the establishment of ester bonds. The membrane that forms is therefore made up of esterified flavonoids. It is demonstrated by the present test that under the action of esterase, there is release over time of procyanidol monomers. The present test consists in bringing together 286 esterase units, constituted by an E 3019 esterase from the porcine pancreas commercially available from Sigma, with crosslinked OPCs according to example la, and after centrifugation at different times. (30 min; 1 hour; 2 hours; 3 hours; 4 hours and 6 hours), the composition of the supernatant is visualized by HPLC chromatography.
L'apparition de monomères dans le surnageant est très nette, ce qui prouve l'action de l'estérase.The appearance of monomers in the supernatant is very clear, which proves the action of esterase.
Les résultats obtenus sont répertoriés au tableau II ci-après :The results obtained are listed in Table II below:
Tableau II : Hydrolyse par une estérase des OPC réticulésTable II: Hydrolysis by an esterase of crosslinked OPCs
On sait que les estérases sont sécrétées à partir des corps d'Ocland dans le stratum granulosum qui vont migrer vers la surface du stratum corneum. La présence des estérases au niveau de la couche superficielle de la peau va permettre une attaque des microcapsules d'OPC réticulés et ainsi libérer les oligomέres procyanidiques doués de propriété tannante et qui vont procéder à une réticulation du collagène présent dans la couche superficielle de la peau et procurer ainsi l'effet lissant de la peau mis en évidence par la présente invention, ce qui est confirmé par les essais de lissage ci-après.It is known that esterases are secreted from Ocland bodies in the stratum granulosum which will migrate to the surface of the stratum corneum. The presence of esterases in the surface layer of the skin will allow an attack on the crosslinked OPC microcapsules and thus release the procyanidic oligomers endowed with tanning properties and which will crosslink the collagen present in the surface layer of the skin. and thus provide the smoothing effect of the skin demonstrated by the present invention, which is confirmed by the smoothing tests below.
Exemple 5 de l'inventionExample 5 of the invention
ESSAIS DE LISSAGE DE LA PEAU Des essais de lissage de la peau ont été réalisés sur un groupe de 32 personnes volontaires.SKIN SMOOTHING TESTS Skin smoothing tests were carried out on a group of 32 volunteers.
Chaque personne a reçu sur des zones de peau différentes de l'un des avant-bras, 4 compositions différentes selon l'invention, telles que préparées à l'exemple 1.
Sur une zone de peau de l'autre avant-bras, elles reçoivent une composition témoin constituée uniquement de l'excipient desdites compositions de l'exemple 1.Each person received on different skin areas of one of the forearms, 4 different compositions according to the invention, as prepared in Example 1. On a skin area of the other forearm, they receive a control composition consisting solely of the excipient of said compositions of Example 1.
Une seule application de chaque composition est réalisée. Deux heures après l'application des compositions, une empreinte de peau sur les zones d'application est réalisée, selon une technique bien connue de l'homme de l'art.Only one application of each composition is made. Two hours after the application of the compositions, a skin impression on the application areas is carried out, according to a technique well known to those skilled in the art.
Une étude du micro-relief dépressionnaire des rides de la peau est ensuite réalisée à partir de ces empreintes, au moyen d'un analyseur d'image classique. Les résultats obtenus, représentant la moyenne des observations par rapport aux empreintes témoins, sont rapportés au tableau III ci-après.A study of the micro-relief of wrinkles in the skin is then carried out using these imprints, using a conventional image analyzer. The results obtained, representing the average of the observations relative to the control fingerprints, are reported in Table III below.
Dans ce tableau, l'indication ± signifie un effet non-significatif,In this table, the indication ± signifies a non-significant effect,
L'indication + signifie un effet de lissage de la peau peu significatif,The + indication signifies an insignificant skin smoothing effect,
L'indication ++ signifie un léger lissage de la peau, L'indication +++ signifie une nette diminution des rides et un lissage de la peau assez satisfaisant,The indication ++ means a slight smoothing of the skin, The indication +++ means a marked reduction in wrinkles and a fairly satisfactory smoothing of the skin,
L'indication ++++ signifie une diminution très nette de la profondeur des rides et un lissage de la peau très satisfaisant.The indication ++++ signifies a very marked reduction in the depth of wrinkles and a very satisfactory smoothing of the skin.
Dans le tableau ffl ci-après, les concentrations en protéine (tensine) et en tanins, à savoir en oligomères proanthocyanidoliques de pépins de raisin réticulés (OPCPR réticulés) sont exprimés en pourcentage en poids, par rapport au poids total de la composition finale.In table ffl below, the concentrations of protein (tensin) and of tannins, namely of proanthocyanidolic oligomers of crosslinked grape seeds (crosslinked OPC PR ) are expressed as a percentage by weight, relative to the total weight of the final composition. .
Tableau III Effet des compositions de l'invention sur le lissage de la peauTable III Effect of the compositions of the invention on the smoothing of the skin
Il résulte du tableau m ci-dessus, que la combinaison de tanins réticulés avec au moins une protéine, ici des protéines de blé, procure un résultat significatif sur lissage de la peau, alors qu'en l'absence de tanins réticulés, cet effet n'est que peu significatif, quel que soit la concentration en protéine testée. De même, en l'absence de protéine, les tanins réticulés n'ont présenté qu'un effet modéré sur lissage de la peau. Il y a donc un effet de synergie mis en évidence entre les tanins réticulés et la protéine combinés entre eux, conformément à l'invention. It follows from Table m above, that the combination of crosslinked tannins with at least one protein, here wheat proteins, gives a significant result on skin smoothness, whereas in the absence of crosslinked tannins, this effect is only of little significance, whatever the protein concentration tested. Likewise, in the absence of protein, the crosslinked tannins showed only a moderate effect on skin smoothness. There is therefore a synergistic effect demonstrated between the crosslinked tannins and the protein combined together, in accordance with the invention.
Exemple 6 de l'inventionExample 6 of the invention
Composition dite "coup d'éclat" pour lisser la peau du visageComposition called "radiance boost" to smooth facial skin
Cette composition est préparée à partir des ingrédients suivants : - microcapsules d'OPC réticulés, selon l'exemple la 1 g,This composition is prepared from the following ingredients: - crosslinked OPC microcapsules, according to example 1 g,
- Carbopol 940® 0.05 g,- Carbopol 940 ® 0.05 g,
- tensine 5g- 5g tensin
-excipient parfumé aqueux avec conservateur qsp 100 g.- aqueous scented excipient with preservative qs 100 g.
Pour préparer cette composition, on solubilise les 5 g de tensine dans environ 40 g d'eau distillée, à froid sous agitation mécanique, puis, on disperse 1 g des microcapsules d'OPC réticulés préparées suivant l'exemple la. Tout en maintenant l'agitation, on complète à 50 g avec un excipient aqueux contenant le parfum et les conservateurs. On ajoute ensuite 50 g d'un gel de Carbopol 940 à 0,1 % neutralisé avec de la soude préparé séparément.To prepare this composition, the 5 g of tensin are dissolved in approximately 40 g of distilled water, cold with mechanical stirring, then 1 g of the crosslinked OPC microcapsules prepared according to Example 1a is dispersed. While maintaining stirring, make up to 50 g with an aqueous excipient containing the perfume and the preservatives. Then added 50 g of a 0.1% Carbopol 940 gel neutralized with sodium hydroxide prepared separately.
On obtient ainsi une composition sous forme d'un gel qui, appliqué sur la peau du visage, produit en quelques minutes un effet tenseur qui lisse la peau en atténuant les rides et les ridules.
A composition is thus obtained in the form of a gel which, applied to the skin of the face, produces in a few minutes a tightening effect which smoothes the skin by reducing wrinkles and fine lines.
Claims
1. Utilisation de tanins réticulés en présence de protéines non- réticulées avec les tanins comme agent cosmétique pour le lissage de la peau et/ou pour l'obtention d'un effet astringent.1. Use of crosslinked tannins in the presence of proteins not crosslinked with the tannins as a cosmetic agent for smoothing the skin and / or for obtaining an astringent effect.
2. Utilisation selon la revendication 1 caractérisée en ce que la protéine est ajoutée à une solution contenant les tanins réticulés préalablement préparés.2. Use according to claim 1 characterized in that the protein is added to a solution containing the crosslinked tannins previously prepared.
3. Utilisation selon l'une des revendications précédentes, caractérisée en ce que les tanins réticulés sont obtenus par réticulation interfaciale, en particulier sous forme de microcapsules ou microparticules et les protéines précitées sont présentes dans une solution, en particulier aqueuse, contenant les tanins préalablement préparés.3. Use according to one of the preceding claims, characterized in that the crosslinked tannins are obtained by interfacial crosslinking, in particular in the form of microcapsules or microparticles and the abovementioned proteins are present in a solution, in particular aqueous, containing the tannins beforehand. prepared.
4. Utilisation selon la revendication 1 à 3, caractérisée en ce que la concentration en tanin est comprise entre 0,001 % et 5 %, de préférence entre4. Use according to claim 1 to 3, characterized in that the tannin concentration is between 0.001% and 5%, preferably between
0,01 % et 5 % et encore mieux entre 0,1 % et 1 %, en poids par rapport au poids total de la composition finale, tandis que la concentration en protéine est comprise entre 0,01 % et 10 %, de préférence entre 0,1 % et 10 %, encore mieux entre 1 % et 5 % en poids par rapport au poids total de la composition finale les contenant. 0.01% and 5% and even better between 0.1% and 1%, by weight relative to the total weight of the final composition, while the protein concentration is between 0.01% and 10%, preferably between 0.1% and 10%, even better between 1% and 5% by weight relative to the total weight of the final composition containing them.
5. Utilisation selon l'une des revendications 1 à 4, caractérisée en ce que le tanin précité est une molécule phénolique hydrosoluble ayant un poids moléculaire compris entre 500 et 3 000 Daltons, en particulier constituée par des oligomères procyanidoliques OPC à l'état pur, ou à l'état de mélange sous forme d'extrait de source naturelle, par exemple des proanthocyanidines de pépins de raisin.5. Use according to one of claims 1 to 4, characterized in that the aforementioned tannin is a water-soluble phenolic molecule having a molecular weight of between 500 and 3,000 Daltons, in particular constituted by procyanidolic oligomers OPC in the pure state , or as a mixture in the form of an extract from a natural source, for example grape seed proanthocyanidins.
6. Utilisation selon l'une des revendications précédentes, caractérisée en ce que la protéine précitée est une protéine compatible avec une application cosmétique ou pharmaceutique, en particulier une protéine d'origine animale humaine ou végétale telle qu'une albumine comme la sérum albumine, l'ovalbumine, l'α-lactalbumine, les globulines, le fibrinogène, la caséine, le collagène, l'atélocollagène, la gélatine, les hydrolysats de gélatine, les peptones, l'hémoglobine, les protéines végétales telles que les protéines de soja, des glytélines sous forme non dégradée ou dégradée, les scléroprotéines solubilisées, des protéines issues du lait sous toutes ses formes, la farine de soja.
6. Use according to one of the preceding claims, characterized in that the aforementioned protein is a protein compatible with a cosmetic or pharmaceutical application, in particular a protein of human or vegetable animal origin such as an albumin such as serum albumin, ovalbumin, α-lactalbumin, globulins, fibrinogen, casein, collagen, atelocollagen, gelatin, gelatin hydrolysates, peptones, hemoglobin, vegetable proteins such as soy proteins , glytelins in non-degraded or degraded form, solubilized scleroproteins, proteins from milk in all its forms, soy flour.
7. Procédé de fabrication d'une composition stable dans le temps contenant des tanins, en particulier des oligomères procyanidoliques ou OPC, en présence d'une protéine, caractérisé en ce qu'on réalise dans une première étape la réticulation des tanins en l'absence de ladite protéine et dans une deuxième étape on mélange les tanins réticulés avec ladite protéine.7. Method of manufacturing a composition stable over time containing tannins, in particular procyanidolic oligomers or OPC, in the presence of a protein, characterized in that one carries out in a first step the crosslinking of tannins in the absence of said protein and in a second step, the crosslinked tannins are mixed with said protein.
8. Procédé selon la revendication 7, caractérisé en ce que la réticulation des tanins a lieu par réticulation interfaciale, en particulier sous forme de microcapsule ou microparticule et les protéines précitées sont présentes dans une solution, en particulier aqueuse, contenant les tanins réticulés préalablement préparés.8. Method according to claim 7, characterized in that the crosslinking of the tannins takes place by interfacial crosslinking, in particular in the form of a microcapsule or microparticle and the abovementioned proteins are present in a solution, in particular aqueous, containing the crosslinked tannins previously prepared. .
9. Procédé de traitement cosmétique de la peau, pour améliorer le lissage de la peau, pour obtenir un effet astringent sur la peau, en particulier un effet raffermissant, caractérisé en ce qu'il comprend l'application sur les zones de la peau concernées d'une quantité efficace de tanins réticulés en présence de protéines non réticulées avec les tanins.9. A method of cosmetic treatment of the skin, to improve the smoothing of the skin, to obtain an astringent effect on the skin, in particular a firming effect, characterized in that it comprises application to the areas of the skin concerned an effective amount of crosslinked tannins in the presence of proteins not crosslinked with the tannins.
10. Procédé selon les revendications 7 à 9, caractérisé en ce que les tanins réticulés sont obtenus par réticulation interfaciale, en particulier sous forme de microcapsules ou microparticules et les protéines précitées sont présentes dans une solution, en particulier aqueuse, contenant les tanins réticulés ayant été séparément préalablement préparés.10. Method according to claims 7 to 9, characterized in that the crosslinked tannins are obtained by interfacial crosslinking, in particular in the form of microcapsules or microparticles and the abovementioned proteins are present in a solution, in particular aqueous, containing the crosslinked tannins having been separately previously prepared.
1 1. Procédé selon l'une des revendications 7 à 10, caractérisé en ce que la concentration en tanin est comprise entre 0,001 % et 5 %, de préférence entre 0,01 % et 5 %, et encore mieux entre 0,1 % et 1 %, en poids par rapport au poids total de la composition, tandis que la concentration en protéine est comprise entre 0,01 % et 10 %, de préférence de 0,1 % et 10 %, encore mieux entre 1 % et 5 % en poids par rapport au poids total de la composition les contenant.1 1. Method according to one of claims 7 to 10, characterized in that the tannin concentration is between 0.001% and 5%, preferably between 0.01% and 5%, and even better between 0.1% and 1%, by weight relative to the total weight of the composition, while the protein concentration is between 0.01% and 10%, preferably 0.1% and 10%, even better between 1% and 5 % by weight relative to the total weight of the composition containing them.
12. Procédé selon l'une des revendications 7 à 11, caractérisé en ce que le tanin précité est une molécule phénolique hydrosoluble ayant un poids moléculaire compris entre 500 et 3 000 Daltons, en particulier constituée par des oligomères procyanidoliques OPC à l'état pur, ou à l'état de mélange sous forme d'extrait de source naturelle, par exemple des proanthocyanidines de pépins de raisin.12. Method according to one of claims 7 to 11, characterized in that the aforementioned tannin is a water-soluble phenolic molecule having a molecular weight of between 500 and 3,000 Daltons, in particular consisting of procyanidolic oligomers OPC in the pure state , or as a mixture in the form of an extract from a natural source, for example grape seed proanthocyanidins.
13. Procédé selon l'une des revendications 7 à 12, caractérisé en ce que la protéine précitée est une protéine compatible avec une application cosmétique
ou pharmaceutique, en particulier une protéine d'origine animale, humaine ou végétale telle qu'une albumine comme la sérum albumine, l'ovalbumine, l'α- lactalbumine, les globulines, le fibrinogène, la caséine, le collagène, l'atélocollagène, la gélatine, les hydrolysats de gélatine, les peptones, l'hémoglobine, les protéines végétales telles que les protéines du soja, des glytélines sous forme non dégradée ou dégradée, les scléroprotéines solubilisées, des protéines issues du lait sous toutes ses formes, la farine de soja.
13. Method according to one of claims 7 to 12, characterized in that the aforementioned protein is a protein compatible with a cosmetic application or pharmaceutical, in particular a protein of animal, human or vegetable origin such as an albumin such as serum albumin, ovalbumin, α-lactalbumin, globulins, fibrinogen, casein, collagen, atelocollagen , gelatin, gelatin hydrolysates, peptones, hemoglobin, vegetable proteins such as soy proteins, glytelins in non-degraded or degraded form, solubilized scleroproteins, proteins from milk in all its forms, soy flour.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9708100A FR2765106B1 (en) | 1997-06-27 | 1997-06-27 | USE OF CROSSLINKED TANNINS IN THE PRESENCE OF NON-CROSSLINKED PROTEINS WITH TANNINS AS COSMETIC AGENTS TO IMPROVE SKIN SMOOTHING AND / OR TO OBTAIN AN ASTRINGENT EFFECT |
FR97/08100 | 1997-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999000110A1 true WO1999000110A1 (en) | 1999-01-07 |
Family
ID=9508546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/001364 WO1999000110A1 (en) | 1997-06-27 | 1998-06-26 | Use of tannins cross-linked in the presence of proteins non-cross-linked with the tannins |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2765106B1 (en) |
WO (1) | WO1999000110A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
CN110868873A (en) * | 2016-07-13 | 2020-03-06 | 尼格食品工程有限公司 | Method for crosslinking biopolymers |
CN114702692A (en) * | 2022-04-01 | 2022-07-05 | 中国科学院青岛生物能源与过程研究所 | Method for improving stability of protein hydrogel |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802812B1 (en) * | 1999-12-22 | 2002-08-23 | Serobiologiques Lab Sa | USE OF RESIDUES FROM THE MANUFACTURE OF WINE FOR THE MANUFACTURE OF COSMETIC AND / OR PHARMACEUTICAL PREPARATIONS. |
FR2841134B1 (en) * | 2002-06-25 | 2004-08-20 | Vincience | COMPOSITION COMPRISING A BIOTRANSFORMATION-MODIFIED CORK EXTRACT |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06336423A (en) * | 1993-05-28 | 1994-12-06 | Kose Corp | External agent for skin |
FR2715582A1 (en) * | 1994-02-02 | 1995-08-04 | Centre Nat Rech Scient | Microcapsules with a crosslinked flavonoid wall and compositions containing them. |
FR2728563A1 (en) * | 1994-12-21 | 1996-06-28 | Ovi Sa | New ester(s) of aromatic poly:hydroxyl cpds. |
FR2731351A1 (en) * | 1995-03-10 | 1996-09-13 | Gattefosse Holding | Compsn. for smoothing skin |
WO1996028008A2 (en) * | 1996-03-19 | 1996-09-19 | Guerlain S.A. | Novel cosmetic or dermatological compositions for controlling skin ageing |
FR2732972A1 (en) * | 1995-04-14 | 1996-10-18 | Mathe Lab | Prodn. of soluble collagen gel compsns. |
-
1997
- 1997-06-27 FR FR9708100A patent/FR2765106B1/en not_active Expired - Lifetime
-
1998
- 1998-06-26 WO PCT/FR1998/001364 patent/WO1999000110A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06336423A (en) * | 1993-05-28 | 1994-12-06 | Kose Corp | External agent for skin |
FR2715582A1 (en) * | 1994-02-02 | 1995-08-04 | Centre Nat Rech Scient | Microcapsules with a crosslinked flavonoid wall and compositions containing them. |
WO1995021018A1 (en) * | 1994-02-02 | 1995-08-10 | Centre National De La Recherche Scientifique (Cnrs) | Microcapsules with walls made of cross-linked plant polyphenols, and compositions containing same |
FR2728563A1 (en) * | 1994-12-21 | 1996-06-28 | Ovi Sa | New ester(s) of aromatic poly:hydroxyl cpds. |
FR2731351A1 (en) * | 1995-03-10 | 1996-09-13 | Gattefosse Holding | Compsn. for smoothing skin |
FR2732972A1 (en) * | 1995-04-14 | 1996-10-18 | Mathe Lab | Prodn. of soluble collagen gel compsns. |
WO1996028008A2 (en) * | 1996-03-19 | 1996-09-19 | Guerlain S.A. | Novel cosmetic or dermatological compositions for controlling skin ageing |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 9508, Derwent World Patents Index; AN 95-057290, XP002054261 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
US7897144B2 (en) | 2001-02-28 | 2011-03-01 | Johnson & Johnson Comsumer Companies, Inc. | Compositions containing legume products |
CN110868873A (en) * | 2016-07-13 | 2020-03-06 | 尼格食品工程有限公司 | Method for crosslinking biopolymers |
CN114702692A (en) * | 2022-04-01 | 2022-07-05 | 中国科学院青岛生物能源与过程研究所 | Method for improving stability of protein hydrogel |
CN114702692B (en) * | 2022-04-01 | 2024-04-23 | 中国科学院青岛生物能源与过程研究所 | Method for improving stability of protein hydrogel |
Also Published As
Publication number | Publication date |
---|---|
FR2765106A1 (en) | 1998-12-31 |
FR2765106B1 (en) | 2000-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1082082B1 (en) | Composition containing an unstable active agent in an oxidizing medium and uses thereof, especially cosmetic uses | |
EP0672404B1 (en) | Organopolysiloxane containing aqueous make-up gel | |
EP0987016B1 (en) | Antiwrinkle composition containing a combination of tensor polymers from synthetic and/or natural origin and dendritic polymers | |
EP0779071B1 (en) | Stable w/o/w emulsion containing a water-sensitive cosmetic and/or dermatologic agent | |
EP1090629B1 (en) | Aescin and dextran sulfate association | |
EP0755672B1 (en) | Silicon composition containing a water-sensitive agent | |
WO1998029091A1 (en) | Cosmetic and/or dermatological composition containing a dispersion of a polymeric system and use of this system as tensor | |
CA2138876A1 (en) | Composition against aging by acting simultaneously on the superficial and deep layers of the skin, and its use | |
EP0944381A1 (en) | Cosmetic and/or dermatological composition containing an aqueous dispersion of a polymeric system and use of this system as tensor | |
EP0755673A1 (en) | Stable composition containing a water-sensitive cosmetic and/or dermatalogic agent | |
EP0691886A1 (en) | Microcapsules with walls made of cross-linked plant polyphenols, and compositions containing same | |
FR2848847A1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN AQUEOUS INSOLUBLE ENZYME AND USES THEREOF | |
FR2673372A1 (en) | COSMETIC COMPOSITION CAPABLE OF FILLING THE DEFECTS OF THE SKIN. | |
WO1996019099A2 (en) | Use of vitamin c or derivatives or analogues thereof for promoting skin elastin synthesis | |
FR2743813A1 (en) | STABLE GELIFIED COMPOSITION WITH HIGH ELECTROLYTE CONTENT | |
FR2787729A1 (en) | Nanocapsules useful in cosmetic or dermatological compositions comprise a lipid core in an anionic polymer shell | |
EP0759293B1 (en) | Stable composition containing an enzyme | |
WO1999000110A1 (en) | Use of tannins cross-linked in the presence of proteins non-cross-linked with the tannins | |
EP0628305B1 (en) | Stable oil-in-water emulsion type cosmetic or dermatologic composition containing at least one vegetable oil comprising at least 40% triglycerides derived from linolic acid | |
EP0946138B1 (en) | Use of a potentilla erecta extract in the cosmetic and pharmaceutical field | |
EP0673238B1 (en) | Use of a simarouba extract to reduce patchy skin pigmentation | |
EP0283349B1 (en) | Process for obtaining tannic principles of vegetable origin, cosmetologic and pharmaceutical composition containing the tannic principle obtained by the process | |
EP0904775B2 (en) | Emulsion containing ascorbic acid and uses in cosmetic and dermatology | |
FR2616325A1 (en) | COMPOSITION CONTAINING HYDROQUINONE AND KOJIC ACID AND PHARMACEUTICAL COMPOSITION, PARTICULARLY DERMATOLOGICAL, WITH DEPIGMENTING OR ANTI-INFLAMMATORY ACTIVITY, OR COSMETIC COMPRISING KOJIC ACID AND HYDROQUINONE | |
FR2820973A1 (en) | COMPOSITION COMPRISING VITAMIN C PREPARED DURING APPLICATION, USE OF ENZYMES FOR THE FORMATION OF VITAMIN C FOR TOPICAL USE AND COSMETIC PROCESSING METHOD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999505341 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |